Fulfillment of Postmarket Commitments and Requirements for New Drugs Approved by the FDA, 2013-2016.
作者信息
Brown Beatrice L, Mitra-Majumdar Mayookha, Darrow Jonathan J, Moneer Osman, Pham Catherine, Avorn Jerry, Kesselheim Aaron S
机构信息
Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Yale School of Medicine, New Haven, Connecticut.
出版信息
JAMA Intern Med. 2022 Oct 3;182(11):1223-6. doi: 10.1001/jamainternmed.2022.4226.
Abstract
摘要
相似文献
1
Fulfillment of Postmarket Commitments and Requirements for New Drugs Approved by the FDA, 2013-2016.
JAMA Intern Med. 2022 Oct 3;182(11):1223-6. doi: 10.1001/jamainternmed.2022.4226.
2
Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.
BMC Med. 2019 Jun 17;17(1):117. doi: 10.1186/s12916-019-1344-3.
3
US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.
Clin Trials. 2021 Aug;18(4):488-499. doi: 10.1177/17407745211005044. Epub 2021 Apr 16.
4
Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
JAMA Intern Med. 2014 Jan;174(1):90-5. doi: 10.1001/jamainternmed.2013.11813.
5
Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
BMJ. 2018 May 24;361:k2031. doi: 10.1136/bmj.k2031.
6
Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.
JAMA. 2017 May 9;317(18):1854-1863. doi: 10.1001/jama.2017.5150.
7
Extending the US Food and Drug Administration's Postmarket Authorities.
JAMA Health Forum. 2023 Jun 2;4(6):e231313. doi: 10.1001/jamahealthforum.2023.1313.
8
Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies.
Mayo Clin Proc Innov Qual Outcomes. 2021 Dec 28;6(1):69-76. doi: 10.1016/j.mayocpiqo.2021.11.009. eCollection 2022 Feb.
9
FDA's Unimproved Enforcement of Postmarketing Requirements and Commitments: Implications for Providers and Patients.
Res Social Adm Pharm. 2020 Jun;16(6):844-847. doi: 10.1016/j.sapharm.2019.11.004. Epub 2019 Nov 7.
10
How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?
Clin Orthop Relat Res. 2016 Apr;474(4):1053-68. doi: 10.1007/s11999-015-4634-x. Epub 2015 Nov 19.
引用本文的文献
1
Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011-2023: a cross-sectional analysis.
BMJ Oncol. 2025 May 19;4(1):e000659. doi: 10.1136/bmjonc-2024-000659. eCollection 2025.
本文引用的文献
1
Trends in the Quality of Evidence Supporting FDA Drug Approvals: Results from a Literature Review.
J Health Polit Policy Law. 2022 Dec 1;47(6):649-672. doi: 10.1215/03616878-10041093.
2
New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence.
Drug Saf. 2022 Apr;45(4):305-318. doi: 10.1007/s40264-022-01152-9. Epub 2022 Feb 19.
3
US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.
Clin Trials. 2021 Aug;18(4):488-499. doi: 10.1177/17407745211005044. Epub 2021 Apr 16.
4
Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
JAMA Intern Med. 2014 Jan;174(1):90-5. doi: 10.1001/jamainternmed.2013.11813.
5
The Food and Drug Administration Amendments Act and postmarketing commitments.
JAMA. 2013 Jul 10;310(2):202-4. doi: 10.1001/jama.2013.7900.
Zotero 插件